How Supriya Lifescience Plans Multi-Pronged Strategy To Take On Chinese Competition
Supriya Lifescience Executive Chairman Satish Waman Wagh outlined a multi-pronged strategy focused on new product launches, capacity expansion, challenging Chinese players in the international market and a strategic foray into the high-margin US market. "We are going to crack the Chinese business through our USFDA plant and we are sure we will take a bigger lead in the US markets," he said. He cited Supriya Lifescience’s focus on regulated markets and its USFDA-compliant manufacturing capabilities.
